SEARCH

SEARCH BY CITATION

References

  • Abad C, Gomariz RP, Waschek JA (2006). Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP. Curr Top Med Chem 6: 151163.
  • Abad C, Tan YV, Lopez R, Nobuta H, Dong H, Phan P et al. (2010). Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 107: 1955519560.
  • Beuming T, Skrabanek L, Niv MY, Mukherjee P, Weinstein H (2005). PDZBase: a protein-protein interaction database for PDZ-domains. Bioinformatics 21: 827828.
  • Bockaert J, Fagni L, Dumuis A, Marin P (2004). GPCR interacting proteins (GIP). Pharmacol Ther 103: 203221.
  • Bourgault S, Vaudry D, Botia B, Couvineau A, Laburthe M, Vaudry H et al. (2008). Novel stable PACAP analogs with potent activity towards the PAC1 receptor. Peptides 29: 919932.
  • Brady AE, Limbird LE (2002). G protein-coupled receptor interacting proteins: emerging role in localization and signal transduction. Cell Signal 14: 297309.
  • Brenneman DE (2007). Neuroprotection: a comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Peptides 28: 17201726.
  • Brenneman DE, Eiden LE (1986). Vasoactive intestinal peptide and electrical activity influence neuronal survival. Proc Natl Acad Sci USA 83: 11591162.
  • Brenneman DE, Gozes I (1996). A femtomolar-acting neuroprotective peptide. J Clin Invest 97: 22992307.
  • Brubaker PL (2007). Incretin-based therapies: mimetics versus protease inhibitors. Trends Endocrinol Metab 18: 240245.
  • Campbell RM, Bongers J, Felix AM (1995). Rational design, synthesis, and biological evaluation of novel growth hormone releasing factor analogues. Biopolymers 37: 6788.
  • Ceraudo E, Murail S, Tan YV, Lacapère JJ, Neumann JM, Couvineau A et al. (2008). The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics. Mol Endocrinol 22: 147155.
  • Christopoulos A, Christopoulos G, Morfis M, Adawela M, Laburthe M, Couvineau A et al. (2002). Novel receptor partners and function of receptor activity-modifying proteins. J Biol Chem 278: 32933297.
  • Chu A, Caldwell JS, Chen YA (2010). Identification and characterization of a small molecule antagonist of human VPAC(2) receptor. Mol Pharmacol 77: 95101.
  • Couvineau A, Rouyer-Fessard C, Darmoul D, Maoret JJ, Carrero I, Ogier-Denis E et al. (1994). Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains. Biochem Biophys Res Commun 200: 769776.
  • Couvineau A, Gaudin P, Maoret JJ, Rouyer-Fessard C, Nicole P, Laburthe M (1995). Highly conserved aspartate 68, tryptophane 73 and glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP. Biochem Biophys Res Commun 206: 246252.
  • Couvineau A, Fabre C, Gaudin P, Maoret JJ, Laburthe M (1996a). Mutagenesis of N-glycosylation sites in the human vasoactive intestinal peptide 1 receptor. Evidence that asparagine 58 or 69 is crucial for correct delivery of the receptor to plasma membrane. Biochemistry 35: 17451752.
  • Couvineau A, Rouyer-Fessard C, Maoret JJ, Gaudin P, Nicole P, Laburthe M (1996b). Vasoactive intestinal peptide (VIP)1 receptor. Three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide histidine isoleucineamide. J Biol Chem 271: 1279512800.
  • Couvineau A, Lacapère JJ, Tan YV, Rouyer-Fessard C, Nicole P, Laburthe M (2003). Identification of cytoplasmic domains of hVPAC1 receptor required for activation of adenylyl cyclase. J Biol Chem 278: 2475924766.
  • Couvineau A, Ceraudo E, Tan YV, Laburthe M (2010). VPAC1 receptor binding site: contribution of photoaffinity labeling approach. Neuropeptides 44: 127132.
  • Dejda A, Sokolowska P, Nowak JZ (2005). Neuroprotective potential of three neuropeptides PACAP, VIP and PHI. Pharmacol Rep 57: 307320.
  • Delgado M, Ganea D (2003). Neuroprotective effect of vasoactive intestinal peptide(VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J 17: 944946.
  • Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP (2001). Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 7: 563568.
  • Delgado M, Pozo D, Ganea D (2004). The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 56: 249290.
  • Dickson L, Finlayson K (2009). VPAC and PAC receptors: from ligands to function. Pharmacol Ther 121: 294316.
  • Dogrukol-Ak D, Tore F, Tuncel N (2004). Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects. Curr Pharm Des 10: 13251340.
  • Du K, Couvineau A, Rouyer-Fessard C, Nicole P, Laburthe M (2002). Human VPAC1 receptor selectivity filter. Identification of a critical domain for restricting secretin binding. J Biol Chem 277: 3701637022.
  • Epstein S (2007). Is cortical bone hip? What determines cortical bone properties? Bone 41: S3S8.
  • Fahrenkrug J, Palle C, Jørgensen J, Ottesen B (1989). Regulatory peptides in the mammalian urogenital system. Experientia Suppl 56: 362381.
  • Fernandez-Montesinos R, Castillo PM, Klippstein R, Gonzalez-Rey E, Mejias JA, Zaderenko AP et al. (2009). Chemical synthesis and characterization of silver-protected vasoactive intestinal peptide nanoparticles. Nanomedicine (Lond) 4: 919930.
  • Fredrikson R, Schiöth B (2006). G Protein-coupled receptors in human genome. In: Rognan D (ed.). Ligand Design for G Protein-Coupled Receptors., Vol. 30. Wiley-VCH: Weinheim, pp. 127.
  • Gee HY, Kim YW, Jo MJ, Namkung W, Kim JY, Park HW et al. (2009). Synaptic scaffolding molecule binds to and regulates vasoactive intestinal polypeptide type-1 receptor in epithelial cells. Gastroenterology 137: 607617.
  • Gilligan PJ, Li YW (2004). Corticotropin-releasing factor antagonists: recent advances and exciting prospects for the treatment of human diseases. Curr Opin Drug Discov Devel 7: 487497.
  • Gomariz RP, Martinez C, Abad C, Leceta J, Delgado M (2001). Immunology of VIP: a review and therapeutical perspectives. Curr Pharm Des 7: 89111.
  • Gonzalez-Rey E, Chorny A, Fernandez-Martin A, Varela N, Delgado M (2005). Vasoactive intestinal peptide family as a therapeutic target for Parkinson's disease. Expert Opin Ther Targets 9: 923929.
  • Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Martin J, Pozo D, Ganea D et al. (2006). Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. Am J Pathol 168: 11791188.
  • Gourlet P, De Neef P, Cnudde J, Waelbroeck M, Robberecht P (1997a). In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides 18: 15551560.
  • Gourlet P, Vandermeers A, Robberecht P, Deschodt-Lanckman M (1997b). Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP-27, but not PACAP-38) degradation by the neutral endopeptidase EC 3.4.24.11. Biochem Pharmacol 54: 509515.
  • Gozes I, Bardea A, Reshef A, Zamostiano R, Zhukovsky S, Rubinraut S et al. (1996). Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci USA 93: 427432.
  • Gozes I, Zamostiano R, Pinhasov A, Bassan M, Giladi E, Steingart RA et al. (2000). A novel VIP responsive gene. Activity dependent neuroprotective protein. Ann N Y Acad Sci 921: 115118.
  • Gozes I, Divinsky I, Pilzer I, Fridkin M, Brenneman DE, Spier AD (2003). From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J Mol Neurosci 20: 315322.
  • Groneberg DA, Springer J, Fischer A (2001). Vasoactive intestinal polypeptide as mediator of asthma. Pulm Pharmacol Ther 14: 391401.
  • Harikumar KG, Morfis MM, Lisenbee CS, Sexton PM, Miller LJ (2006). Constitutive formation of oligomeric complexes between family B G protein-coupled vasoactive intestinal polypeptide and secretin receptors. Mol Pharmacol 69: 363373.
  • Hoare SRJ (2005). Mechanism of peptide and nonpeptide ligand binding to class B G-protein-coupled receptors. Drug Discov Today 10: 417427.
  • Inzucchi SE, McGuire DK (2008). New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond. Circulation 117: 574584.
  • Jeppesen PB (2006). Glucagon-like peptide-2: update of the recent clinical trials. Gastroenterology 130: S127S131.
  • Kumar S, Pioszak A, Zhang C, Swaminathan K, Xu HE (2011). Crystal Structure of the PAC1R Extracellular Domain Unifies a Consensus Fold for Hormone Recognition by Class B G-Protein Coupled Receptors. PLoS ONE 6: e19682.
  • Kurakin A, Swistowski A, Wu SC, Bredesen DE (2007). The PDZ domain as a complex adaptive system. PLoS ONE 2: e953.
  • Laburthe M, Couvineau A, Marie JC (2002). VPAC receptors for VIP and PACAP. Receptors Channels 8: 137153.
  • Laburthe M, Couvineau A, Tan V (2007). Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 28: 16311639.
  • Lutz EM, Sheward WJ, West KM, Morrow JA, Fink G, Harmar AJ (1993). The VIP2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 334: 38.
  • Mahon MJ, Shimada M (2005). Calmodulin interacts with the cytoplasmic tails of the parathyroid hormone 1 receptor and a sub-set of class b G-protein coupled receptors. FEBS Lett 579: 803807.
  • Marie JC, Rouyer-Fessard C, Couvineau A, Nicole P, Devaud H, El Benna J et al. (2003). Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor. Mol Pharmacol 64: 15651574.
  • Moody TW, Gozes I (2007). Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer. Curr Pharm Des 13: 10991104.
  • Moreno D, Gourlet P, De Neef P, Cnudde J, Waelbroeck M, Robberecht P (2000). Development of selective agonists and antagonists for the human vasoactive intestinal peptide VPAC2 receptor. Peptides 21: 15431549.
  • Mulder JE, Kolatkar NS, LeBoff MS (2006). Drug insight: existing and emerging therapies for osteoporosis. Nat Clin Pract Endocrinol Metab 2: 670680.
  • Neumann JM, Couvineau A, Murail S, Lacapère JJ, Jamin N, Laburthe M (2008). Class-B GPCR activation: is ligand helix-capping the key? Trends Biochem Sci 33: 314319.
  • Nicole P, Lins L, Rouyer-Fessard C, Drouot C, Fulcrand P, Thomas A et al. (2000). Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. J Biol Chem 275: 2400324012.
  • Onyüksel H, Mohanty PS (2009). Rubinstein I. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer. Int J Pharm 365: 157161.
  • Parthier C, Reedtz-Runge S, Rudolph R, Stubbs MT (2009). Passing the baton in class B GPCRs: peptide hormone activation via helix induction? Trends Biochem Sci 34: 303310.
  • Robberecht P, Waelbroeck M (1998). A critical view of the method for characterization of the VIP/PACAP receptor subclasses. Ann N Y Acad Sci 865: 157163.
  • Said SI, Mutt V (1970). Polypeptide with broad biological activity: isolation from small intestine. Science 169: 12171218.
  • Sexton PM, Poyner DR, Simms J, Christopoulos A, Hay DL (2009). Modulating receptor function through RAMPs: can they represent drug targets in themselves? Drug Discov Today 14: 413419.
  • Sheng M, Sala C (2001). PDZ domains and the organization of supramolecular complexes. Annu Rev Neurosci 24: 129.
  • Tan YV, Couvineau A, Van Rampelbergh J, Laburthe M (2003). Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor. J Biol Chem 278: 3653136536.
  • Tan YV, Couvineau A, Laburthe M (2004). Diffuse pharmacophoric domains of vasoactive intestinal peptide (VIP) and further insights into the interaction of VIP with the N-terminal ectodomain of human VPAC1 receptor by photoaffinity labeling with [Bpa6]-VIP. J Biol Chem 279: 3888938894.
  • Tan YV, Couvineau A, Murail S, Ceraudo E, Neumann JM, Lacapère JJ et al. (2006). Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor. Photoaffinity, NMR, and molecular modeling. J Biol Chem 281: 1279212798.
  • Vacic V, McCarthy S, Malhotra D, Murray F, Chou HH, Peoples A et al. (2011). Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. Nature 471: 499503.
  • Vaudry H, Laburthe M (2006). VIP, PACAP, and related peptides. From gene to therapy. Ann N Y Acad Sci 1070: 1633.
  • Xia M, Sreedharan SP, Bolin DR, Gaufo GO, Goetzl EJ (1997). Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J Pharmacol Exp Ther 281: 629633.
  • Yadav M, Huang MC, Goetzl EJ (2011). VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis. Cell Immunol 267: 124132.